How much funding has Adaptimmune raised?

Adaptimmune has raised $104.0M in total funding, most recently a Venture Round.

Who are Adaptimmune's investors?

Adaptimmune's investors include Hercules Capital, New Enterprise Associates, F-Prime Capital, Wellington Management, OrbiMed, Eight Roads Ventures.

When was Adaptimmune founded?

Adaptimmune was founded in 2008.

Where is Adaptimmune headquartered?

Adaptimmune is headquartered in Philadelphia.

What industry is Adaptimmune in?

Adaptimmune operates in Biotech, Healthcare.

How many employees does Adaptimmune have?

Adaptimmune has 201-500 employees.

Adaptimmune

IPO

Arming cells. Against cancer. For good.

Public · Philadelphia · Founded 2008 · $104.0M raised

Biotech

Healthcare

Headquarters: Philadelphia
Employees: 201–500
Founded: 2008
Business Model: B2B
Website: adaptimmune.com

Total Funding: $104.0M
Last Round: $104.0M Venture RoundSep 2014
Rounds: 1
Type: Public

About

Founded in 2008, Adaptimmune develops novel T-cell receptor (TCR-T) immunotherapies for cancer treatment. The company pioneered the first FDA-approved engineered cell therapy for solid tumors (TECELRA). Headquartered in Philadelphia with UK operations, it employs approximately 300-400 people across its integrated cell therapy platform.

Summary

Adaptimmune is a Biotech company based in Philadelphia, founded in 2008. It has raised $104.0M in total across 1 round, most recently a $104.0M Venture Round round in Sep 2014. Investors include Hercules Capital, New Enterprise Associates and F-Prime Capital.

LinkedIn X (Twitter)